ATGC said Thursday that it signed a strategic partnership license and supply agreement with RELIFE, an Italian biopharma firm, for its botulinum toxin type A (ATGC-100) as part of its strategic entry into Europe.

ATGC signed a strategic partnership license and supply agreement with RELIFE for its novel botulinum toxin type A, ATGC-100, to enter the European market.
ATGC signed a strategic partnership license and supply agreement with RELIFE for its novel botulinum toxin type A, ATGC-100, to enter the European market.

Under the agreement, ATGC will grant RELIFE exclusive rights to develop, register, promote, distribute, and market the novel botulinum toxin type A candidate for medical aesthetic indications in select geographical areas.

“We are proud to announce that we have signed this exclusive license agreement with RELIFE, part of the Menarini Group which is Italy’s largest multinational biopharmaceutical company,” said CEO Jang Sung-su of ATGC. “With a strong European and global presence, this agreement marks a step forward for ATGC and the development of the novel botulinum toxin candidate, ATGC-100.”

“We are pleased to undertake this strategic partnership and agreement with ATGC, a company with years of dedication and experience in botulinum toxin development.” said Silvester Sven Rossmann, global head of RELIFE.

Rossmann added, “We are confident that the longstanding commercial experience of Menarini Group as a trustworthy, reliable and strategic partner will facilitate a successful product launch and strengthen RELIFE’s comprehensive aesthetic medicine portfolio.”

Copyright © KBR Unauthorized reproduction, redistribution prohibited